A phase 3 study evaluating a novel fixed-dose combination of extended release pramipexole and rasagiline (P2B001) in adults with early Parkinson disease met its primary and key secondary endpoints.
/PRNewswire/ Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved.
/PRNewswire/ Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved.
/PRNewswire/ Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved.
Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a marketed